[Convalescent plasma as a therapy for severe COVID-19 pneumonia]
- PMID: 33481727
[Convalescent plasma as a therapy for severe COVID-19 pneumonia]
Abstract
The COVID-19 pandemic presented high mortality from its beginning, without effective treatment for seriously ill patients. Build on the experience in Argentine hemorrhagic fever with convalescent plasma, we incorporated 90 patients with COVID-19, of which 87 were evaluable, into a multicenter study. We collected 397 plasma donations from 278 convalescent donors. Patients received plasma with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective; 77% were male, age 54 ± 15.6 y/o (range 27-85), body mass index 29.7 ± 4.4; hypertension 39% and diabetes 20.7%; 19.5% had an immunosuppressive condition, 23% were health workers. Plasma was administered to 55 (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and to 32 patients (37%) on mechanical ventilation. The 28-day survival rate was 80%; 91% in patients infused on spontaneous breathing and 63% in those on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia clinical scale at 7 and 14 days, and in PaO2 / FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation. They are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.
La pandemia de COVID-19, presentó desde su inicio elevada mortalidad, sin tratamiento efectivo para pacientes graves. Basados en experiencia previa con plasma de convaleciente en fiebre hemorrágica Argentina, incorporamos a un estudio multicéntrico 90 pacientes con COVID-19 de los que 87 fueron evaluables. Colectamos 397 donaciones de plasma de 278 convalecientes. El plasma fue suministrado con una concentración de IgG de 0.7-0.8 (medidos por quimioluminiscencia Abbott) por cada 10 kg/ peso. La supervivencia a 28 días fue la variable de resultado primario. El 77% fueron varones, edad 54 ± 15.6 años (rango: 27-85); índice de masa corporal de 29.7 ± 4.4; tenían hipertensión 39%, diabetes 20.7%; 19.5% tenían alguna condición de inmunosupresión, y el 23% era personal de salud. Se administró plasma a 55 (63%) en respiración espontánea con oxígeno (con máscara reservorio en 80%), y a 32 (37%) en ventilación mecánica. La supervivencia global a 28 días fue del 80%; 91% en quienes recibían oxígeno suplementario y 63% en los que permanecían en ventilación mecánica (p = 0.0002). Hubo mejora significativa en la escala clínica de neumonía de la OMS a los 7 y a los 14 días. La ferritina, LDH y PaO2/FiO2, mejoraron en la semana post-infusión. Observamos un episodio de sobrecarga de volumen circulatorio y una reacción febril, leves. Las infusiones de plasma de convaleciente son factibles, seguras y potencialmente efectivas, especialmente antes de requerir ventilación mecánica. Constituyen una opción clínica atractiva para tratar formas graves de COVID-19 hasta que estén disponibles otras terapias eficaces.
Keywords: COVID-19 convalescent plasma treatment; COVID-19 pandemic; severe acute respiratory syndrome coronavirus 2.
Similar articles
-
Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection.South Med J. 2023 May;116(5):427-433. doi: 10.14423/SMJ.0000000000001546. South Med J. 2023. PMID: 37137479 Free PMC article. Review.
-
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6. Trials. 2021. PMID: 34001174 Free PMC article.
-
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y. Trials. 2020. PMID: 33023671 Free PMC article.
-
Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.Eur J Immunol. 2020 Oct;50(10):1447-1453. doi: 10.1002/eji.202048723. Epub 2020 Sep 22. Eur J Immunol. 2020. PMID: 32886952 Review.
-
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783. JAMA. 2020. PMID: 32219428 Free PMC article.
Cited by
-
A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients.Cureus. 2022 Sep 7;14(9):e28914. doi: 10.7759/cureus.28914. eCollection 2022 Sep. Cureus. 2022. PMID: 36237760 Free PMC article. Review.
-
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview.Vaccines (Basel). 2021 Nov 12;9(11):1317. doi: 10.3390/vaccines9111317. Vaccines (Basel). 2021. PMID: 34835248 Free PMC article. Review.
-
Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression.Br J Anaesth. 2021 Dec;127(6):834-844. doi: 10.1016/j.bja.2021.07.033. Epub 2021 Aug 30. Br J Anaesth. 2021. PMID: 34579942 Free PMC article.
-
Effect of time and titer in convalescent plasma therapy for COVID-19.iScience. 2021 Aug 20;24(8):102898. doi: 10.1016/j.isci.2021.102898. Epub 2021 Jul 22. iScience. 2021. PMID: 34316549 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical